ZA200509952B - Indazole derivatives - Google Patents
Indazole derivatives Download PDFInfo
- Publication number
- ZA200509952B ZA200509952B ZA200509952A ZA200509952A ZA200509952B ZA 200509952 B ZA200509952 B ZA 200509952B ZA 200509952 A ZA200509952 A ZA 200509952A ZA 200509952 A ZA200509952 A ZA 200509952A ZA 200509952 B ZA200509952 B ZA 200509952B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- cancer
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 52
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 32
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 28
- 125000001589 carboacyl group Chemical group 0.000 claims abstract description 23
- 125000003118 aryl group Chemical group 0.000 claims abstract description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 18
- 125000003435 aroyl group Chemical group 0.000 claims abstract description 12
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims abstract description 11
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims description 50
- -1 nitro, hydroxy, carboxy Chemical group 0.000 claims description 36
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010073069 Hepatic cancer Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 201000009036 biliary tract cancer Diseases 0.000 claims description 6
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 210000000214 mouth Anatomy 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 201000005443 oral cavity cancer Diseases 0.000 claims description 6
- 201000008968 osteosarcoma Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 201000008006 pharynx cancer Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 22
- 239000000126 substance Substances 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 125000001424 substituent group Chemical group 0.000 description 35
- 150000002473 indoazoles Chemical class 0.000 description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000005427 anthranyl group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000006640 cycloheptyl carbonyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005485 noradamantyl group Chemical group 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003203508 | 2003-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200509952B true ZA200509952B (en) | 2006-09-27 |
Family
ID=34113614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200509952A ZA200509952B (en) | 2003-07-30 | 2005-12-07 | Indazole derivatives |
Country Status (15)
Country | Link |
---|---|
US (2) | US7470717B2 (es) |
EP (1) | EP1652842B1 (es) |
JP (1) | JP4335212B2 (es) |
KR (1) | KR20060119705A (es) |
CN (1) | CN100390149C (es) |
AT (1) | ATE553092T1 (es) |
AU (1) | AU2004260756B2 (es) |
BR (1) | BRPI0408876A (es) |
CA (1) | CA2518950A1 (es) |
EA (1) | EA010165B1 (es) |
ES (1) | ES2384568T3 (es) |
MX (1) | MXPA05011420A (es) |
NO (1) | NO20055333L (es) |
WO (1) | WO2005012257A1 (es) |
ZA (1) | ZA200509952B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003212335B8 (en) | 2002-03-13 | 2009-04-23 | Janssen Pharmaceutica N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
DK1485354T3 (da) | 2002-03-13 | 2008-09-01 | Janssen Pharmaceutica Nv | Sulfonylamino-derivater som nye inhibitorer af histandeacetylase |
BR0307606A (pt) | 2002-03-13 | 2004-12-21 | Janssen Pharmaceutica Nv | Derivados de piperazinila, piperidinila e morfolinila como inibidores de histona desacetilase |
NZ534831A (en) | 2002-03-13 | 2007-01-26 | Janssen Pharmaceutica Nv | Carbonylamino-derivatives having histone deacetylase (HDAC) inhibiting enzymatic activity |
JP4335212B2 (ja) * | 2003-07-30 | 2009-09-30 | 協和発酵キリン株式会社 | インダゾール誘導体 |
WO2006010750A1 (en) | 2004-07-28 | 2006-02-02 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
ES2426482T3 (es) * | 2005-01-27 | 2013-10-23 | Kyowa Hakko Kirin Co., Ltd. | Inhibidor de IGF-1R |
WO2006118257A1 (ja) * | 2005-04-28 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | インダゾール-3-イルメチルホスホニウム塩の製造法 |
EP1885710B1 (en) | 2005-05-18 | 2015-08-19 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
EP1943232B1 (en) | 2005-10-27 | 2011-05-18 | Janssen Pharmaceutica NV | Squaric acid derivatives as inhibitors of histone deacetylase |
AU2007206942B2 (en) | 2006-01-19 | 2012-08-23 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
SI1981874T1 (sl) | 2006-01-19 | 2009-10-31 | Janssen Pharmaceutica Nv | Aminofenilni derivati kot novi inhibitorji histon deacetilaze |
JP5137849B2 (ja) | 2006-01-19 | 2013-02-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体 |
AU2007206944B2 (en) | 2006-01-19 | 2012-08-23 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
CN101484427A (zh) | 2006-06-30 | 2009-07-15 | 协和发酵麒麟株式会社 | Abl激酶抑制剂 |
EP2036894A4 (en) * | 2006-06-30 | 2011-01-12 | Kyowa Hakko Kirin Co Ltd | AURORA INHIBITOR |
JPWO2008020606A1 (ja) * | 2006-08-16 | 2010-01-07 | 協和発酵キリン株式会社 | 血管新生阻害剤 |
GB0619325D0 (en) | 2006-09-30 | 2006-11-08 | Univ Strathclyde | New compounds |
CA2680161A1 (en) | 2007-03-05 | 2008-09-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
JPWO2008111441A1 (ja) | 2007-03-05 | 2010-06-24 | 協和発酵キリン株式会社 | 医薬組成物 |
WO2008114812A1 (ja) * | 2007-03-19 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | Jak阻害剤 |
WO2009143404A1 (en) * | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
CN103804382A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
CN103804306A (zh) * | 2012-11-12 | 2014-05-21 | 韩文毅 | 一类治疗糖尿病的化合物及其用途 |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
MX2018003462A (es) | 2015-09-22 | 2018-09-06 | Graybug Vision Inc | Compuestos y composiciones para el tratamiento de trastornos oculares. |
JP7217022B2 (ja) | 2017-03-23 | 2023-02-02 | グレイバグ ビジョン インコーポレイテッド | 眼障害の治療のための薬物及び組成物 |
EP3621654A4 (en) | 2017-05-10 | 2021-02-17 | Graybug Vision, Inc. | PROLONGED-RELEASE MICROPARTICLES AND SUSPENSIONS OF THESE INTENDED FOR MEDICAL THERAPY |
US11629139B2 (en) | 2017-09-08 | 2023-04-18 | President And Fellows Of Harvard College | Small molecule inhibitors of Ebola and Lassa fever viruses and methods of use |
US11566004B2 (en) * | 2018-07-23 | 2023-01-31 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0232059A (ja) * | 1988-07-18 | 1990-02-01 | Kyowa Hakko Kogyo Co Ltd | インダゾール誘導体 |
PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
US7238853B2 (en) * | 2000-07-14 | 2007-07-03 | Unicrop Ltd | Molecular mechanisms for gene containment in plants |
US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
ATE449763T1 (de) * | 2001-04-16 | 2009-12-15 | Eisai R&D Man Co Ltd | 1h-indazolverbindungen die jnk hemmen |
EP1510516A4 (en) * | 2002-05-31 | 2005-11-02 | Eisai Co Ltd | PYRAZOL COMPOUND AND MEDICAL COMPOSITION CONTAINING THEM |
CA2508319A1 (en) * | 2002-12-03 | 2004-06-17 | Kyowa Hakko Kogyo Co., Ltd. | Jnk inhibitors |
JP4335212B2 (ja) * | 2003-07-30 | 2009-09-30 | 協和発酵キリン株式会社 | インダゾール誘導体 |
-
2004
- 2004-07-30 JP JP2005512586A patent/JP4335212B2/ja not_active Expired - Fee Related
- 2004-07-30 CN CNB2004800104880A patent/CN100390149C/zh not_active Expired - Fee Related
- 2004-07-30 AU AU2004260756A patent/AU2004260756B2/en not_active Ceased
- 2004-07-30 EA EA200600333A patent/EA010165B1/ru not_active IP Right Cessation
- 2004-07-30 EP EP04771301A patent/EP1652842B1/en not_active Not-in-force
- 2004-07-30 KR KR1020057018013A patent/KR20060119705A/ko active IP Right Grant
- 2004-07-30 CA CA002518950A patent/CA2518950A1/en not_active Abandoned
- 2004-07-30 US US10/548,475 patent/US7470717B2/en not_active Expired - Fee Related
- 2004-07-30 ES ES04771301T patent/ES2384568T3/es active Active
- 2004-07-30 WO PCT/JP2004/011287 patent/WO2005012257A1/ja active Application Filing
- 2004-07-30 MX MXPA05011420A patent/MXPA05011420A/es active IP Right Grant
- 2004-07-30 BR BRPI0408876-0A patent/BRPI0408876A/pt not_active IP Right Cessation
- 2004-07-30 AT AT04771301T patent/ATE553092T1/de active
-
2005
- 2005-11-11 NO NO20055333A patent/NO20055333L/no unknown
- 2005-12-07 ZA ZA200509952A patent/ZA200509952B/en unknown
-
2008
- 2008-11-21 US US12/275,614 patent/US7919517B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO20055333L (no) | 2005-11-11 |
BRPI0408876A (pt) | 2006-04-11 |
US20070117856A1 (en) | 2007-05-24 |
AU2004260756B2 (en) | 2010-03-25 |
ES2384568T3 (es) | 2012-07-09 |
CN100390149C (zh) | 2008-05-28 |
CN1777590A (zh) | 2006-05-24 |
WO2005012257A1 (ja) | 2005-02-10 |
JP4335212B2 (ja) | 2009-09-30 |
US7919517B2 (en) | 2011-04-05 |
US20090082348A1 (en) | 2009-03-26 |
ATE553092T1 (de) | 2012-04-15 |
EA200600333A1 (ru) | 2006-06-30 |
KR20060119705A (ko) | 2006-11-24 |
CA2518950A1 (en) | 2005-02-10 |
EA010165B1 (ru) | 2008-06-30 |
EP1652842B1 (en) | 2012-04-11 |
AU2004260756A1 (en) | 2005-02-10 |
EP1652842A4 (en) | 2008-10-01 |
JPWO2005012257A1 (ja) | 2006-09-14 |
EP1652842A1 (en) | 2006-05-03 |
MXPA05011420A (es) | 2005-12-12 |
US7470717B2 (en) | 2008-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200509952B (en) | Indazole derivatives | |
US11945815B2 (en) | PTPN11 inhibitors | |
US10280171B2 (en) | Heterocyclic inhibitors of PTPN11 | |
CN108349981B (zh) | 新型的吡唑并[3,4-d]嘧啶化合物或其盐 | |
AU2015360360B2 (en) | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | |
EP1847532B1 (en) | Igf-1r inhibitor | |
EP1178965B1 (en) | Quinoline derivatives as inhibitors of mek enzymes | |
EP3712151A1 (en) | Spiro aromatic ring compound and application thereof | |
JP2021512131A (ja) | 抗ガン剤として有用な置換キナゾリン誘導体と置換ピリドピリミジン誘導体 | |
EP3569602B1 (en) | Imidazopyrazine compound, preparation method therefor and use thereof | |
JP5901634B2 (ja) | キナゾリン化合物及びその使用方法 | |
CN106458982A (zh) | 作为irak4抑制剂的吲唑化合物 | |
CN101981037A (zh) | 吡唑并嘧啶pi3k抑制剂化合物及使用方法 | |
WO2022222964A1 (zh) | 吡啶衍生物及其在医药上的应用 | |
CN114423753A (zh) | 作为cd38抑制剂的杂双环酰胺 | |
CN111247152A (zh) | 作为激酶抑制剂的环状亚氨基嘧啶衍生物 | |
KR20220041050A (ko) | 피라졸 화합물의 비흡습성 결정질 염, 및 이의 약제학적 조성물 및 용도 | |
AU2004260759A1 (en) | Protein kinase inhibitors | |
EP2036893A1 (en) | Abl KINASE INHIBITOR | |
CN115385938A (zh) | 苯并嘧啶类化合物、其制备方法及其在医药上的应用 | |
EP0115049A1 (en) | 1-Ethyl-6,8-difluoro-1,4-dihydro-7-(1-imidazolyl)-4-oxoquinoline-3-carboxylic acid derivatives, process for preparing the same and anti-microbial compositions | |
CA2735417A1 (en) | Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivatives containing phenyl group having sulfonic acid ester structure introduced therein as substituent | |
HU202106B (en) | Process for producing pharmaceutical compositions containing pyrazolin derivatives | |
JP2001526215A (ja) | Rambaおよびトコフェロールの組み合わせ剤 | |
US20090209537A1 (en) | Aurora inhibitors |